The effects of an open design on trial participant recruitment, compliance and retention--a randomized controlled trial comparison with a blinded, placebo-controlled design - PubMed (original) (raw)
Clinical Trial
The effects of an open design on trial participant recruitment, compliance and retention--a randomized controlled trial comparison with a blinded, placebo-controlled design
Alison Avenell et al. Clin Trials. 2004.
Abstract
Background: In randomized trials there may be no overriding reason whether or not to have a placebo control.
Purpose: We assessed the effects of an open trial design (no placebo and people know what tablets they are given) compared with a blinded, placebo-controlled design on recruitment, compliance and retention within a randomized trial of secondary osteoporotic fracture prevention.
Methods: We undertook a randomized controlled comparison nested within a placebo-controlled trial of nutritional supplementation amongst people aged 70 years or over who had previously sustained a fracture, recruited in a UK teaching hospital. Randomization was 2:1 in favour of the blinded, placebo-controlled trial design.
Results: From 180 eligible participants randomized to receive information based on the open trial design, 134 (74.4%) consented to take part, compared with 233 (65.1%) of 358 people randomized to the blinded, placebo-controlled design (difference 9.4%, 95% confidence interval 1.3-17.4%). Reluctance to take a placebo and the desire to know tablet allocation were reasons given for not taking part in the blinded, placebo-controlled design. There was no significant difference in tablet compliance. Open trial participants were more likely to remain in the trial for one year (difference 13.9%, 95% confidence interval 3.1-24.6%), mainly reflecting the high retention of the open trial no tablet group compared to the open trial tablet group (difference 23.6%, 95% confidence interval 11.9-35.2%). The odds ratio for reporting an adverse event in the open trial compared to the blinded, placebo-controlled design was 0.64 (95% confidence interval 0.28-1.49), and for reporting a fracture was 0.81 (0.36-1.85).
Conclusions: We conclude that using an open trial design may enhance participant recruitment and retention and thus improve generalizability and statistical power, but withdrawal rates may differ between the study allocations and may threaten the internal validity of the trial.
Similar articles
- Prevention of bone loss and vertebral fractures in patients with chronic epilepsy--antiepileptic drug and osteoporosis prevention trial.
Lazzari AA, Dussault PM, Thakore-James M, Gagnon D, Baker E, Davis SA, Houranieh AM. Lazzari AA, et al. Epilepsia. 2013 Nov;54(11):1997-2004. doi: 10.1111/epi.12351. Epub 2013 Sep 6. Epilepsia. 2013. PMID: 24010637 Clinical Trial. - Effects of calcium supplementation on clinical fracture and bone structure: results of a 5-year, double-blind, placebo-controlled trial in elderly women.
Prince RL, Devine A, Dhaliwal SS, Dick IM. Prince RL, et al. Arch Intern Med. 2006 Apr 24;166(8):869-75. doi: 10.1001/archinte.166.8.869. Arch Intern Med. 2006. PMID: 16636212 Clinical Trial. - Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial.
Cheung AM, Tile L, Cardew S, Pruthi S, Robbins J, Tomlinson G, Kapral MK, Khosla S, Majumdar S, Erlandson M, Scher J, Hu H, Demaras A, Lickley L, Bordeleau L, Elser C, Ingle J, Richardson H, Goss PE. Cheung AM, et al. Lancet Oncol. 2012 Mar;13(3):275-84. doi: 10.1016/S1470-2045(11)70389-8. Epub 2012 Feb 7. Lancet Oncol. 2012. PMID: 22318095 Clinical Trial. - Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis.
Tang BM, Eslick GD, Nowson C, Smith C, Bensoussan A. Tang BM, et al. Lancet. 2007 Aug 25;370(9588):657-66. doi: 10.1016/S0140-6736(07)61342-7. Lancet. 2007. PMID: 17720017 Review. - Prevention of osteoporotic fractures in the elderly.
Wilkins CH, Birge SJ. Wilkins CH, et al. Am J Med. 2005 Nov;118(11):1190-5. doi: 10.1016/j.amjmed.2005.06.046. Am J Med. 2005. PMID: 16271899 Review.
Cited by
- Attitudes of Potential Participants Towards Molecular Therapy Trials in Huntington's Disease.
Bardakjian TM, Naczi KF, Gonzalez-Alegre P. Bardakjian TM, et al. J Huntingtons Dis. 2019;8(1):79-85. doi: 10.3233/JHD-180328. J Huntingtons Dis. 2019. PMID: 30689592 Free PMC article. - The Influences of Macronutrients on Bone Mineral Density, Bone Turnover Markers, and Fracture Risk in Elderly People: A Review of Human Studies.
Je M, Kang K, Yoo JI, Kim Y. Je M, et al. Nutrients. 2023 Oct 16;15(20):4386. doi: 10.3390/nu15204386. Nutrients. 2023. PMID: 37892460 Free PMC article. Review. - Vitamin D supplementation for prevention of mortality in adults.
Bjelakovic G, Gluud LL, Nikolova D, Whitfield K, Wetterslev J, Simonetti RG, Bjelakovic M, Gluud C. Bjelakovic G, et al. Cochrane Database Syst Rev. 2014 Jan 10;2014(1):CD007470. doi: 10.1002/14651858.CD007470.pub3. Cochrane Database Syst Rev. 2014. PMID: 24414552 Free PMC article. Review. - Vitamin D Supplementation and Fractures in Adults: A Systematic Umbrella Review of Meta-Analyses of Controlled Trials.
Chakhtoura M, Bacha DS, Gharios C, Ajjour S, Assaad M, Jabbour Y, Kahale F, Bassatne A, Antoun S, Akl EA, Bouillon R, Lips P, Ebeling PR, El-Hajj Fuleihan G. Chakhtoura M, et al. J Clin Endocrinol Metab. 2022 Feb 17;107(3):882-898. doi: 10.1210/clinem/dgab742. J Clin Endocrinol Metab. 2022. PMID: 34687206 Free PMC article. - Usefulness of combining intermittent hypoxia and physical exercise in the treatment of obesity.
Urdampilleta A, González-Muniesa P, Portillo MP, Martínez JA. Urdampilleta A, et al. J Physiol Biochem. 2012 Jun;68(2):289-304. doi: 10.1007/s13105-011-0115-1. Epub 2011 Nov 3. J Physiol Biochem. 2012. PMID: 22045452 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical